Computational methods to estimate drug development parameters

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 1, 2001, Pages 102-109

  Podlogar, B L ^a   Muegge, I ^a   Brice, L J ^a  

^a Transcept Pharmaceuticals Inc   (United States)

Author keywords

Absorption; ADME; Blood brain barrier; Computational; Drug likeness; Metabolism; PKa; Sol ubility; Toxicology

Indexed keywords

BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TOXICITY; PHYSICAL CHEMISTRY; PKA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; MATHEMATICAL COMPUTING;

EID: 0035153842     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA
2. QSAR using 2D descriptors and TRIPOS' SIMCA
3. Computer automated log P calculations based on an extended group contribution approach
4. QSAR model for drug human oral bioavailability
5. QSAR and CoMFA: A perspective on the practical application to drug discovery
6. Lipids lipophilic drugs and oral drug delivery - Some emerging concepts
7. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
8. Dissolution testing as a prognostic tool for oral absorption: Immediate release dosage forms
9. Simulation models to predict oral drug absorption from in vitro data
10. Development of predictive pharmacokinetic simulation models for drug discovery
11. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: Oral bioavailability
12. Using theoretical descriptors in quantitative structure-activity relationships: Some toxicological indices
13. Design principles for orally bioavailable drugs
14. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
15. Estimation of aqueous solubility of organic molecules by the group contribution approach. Application to the study of biodegradation
16. Prediction of drug solubility from Monte Carlo simulations
17. Prediction of aqueous solubility in drug design
18. CNS drug design based on principles of blood-brain barrier transport
19. 2 receptor histamine antagonists
20. Hydrogen bonding: 33 factors that influence the distribution of solutes between blood and brain
21. Computation of brain-blood partitioning of organic solute via free energy calculations
22. Prediction of the blood brain distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling
23. Predicting blood-brain barrier permeation from three-dimensional molecular structure
24. Designing libraries with CNS activity
25. Potential drugs and non-drugs: Prediction and identification of important structural features
26. Calculating log P (oct) with no missing fragments, the problem of estimating new interaction parameters
27. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics
28. Virtual screening of molecular properties: A comparison of LogP calculators
29. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
30. Evaluation and prediction of drug permeation
31. Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity and mutagenicity using MULTI-CASE
32. Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program
33. Accelerated toxicity screening using NMR and pattern recognition-based methods
34. High-throughput toxicology: Practical considerations
35. Fundamental structural alerts to potential carcinogenicity or non-carcinogenicity
36. Computational methods for the prediction of drug toxicity
37. Predicting human safety: Screening and computational approaches
38. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR
39. Use and value of metabolism databases
40. bm3)
41. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolic predictions using a combined protein and pharmacophore model for CYP2D6
42. Small molecule docking and scoring
43. Predictive models for cytochrome P450 mediated metabolism
44. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors
45. Ligand: Chemical database for enzyme reactions
46. Web alert: The chemistry of metabolic and toxicological processes
47. Computational methods for the prediction of 'drug-likeness'
48. Virtual screening - An overview
49. Recognizing molecules with drug-like properties
50. Property distribution of drug-related chemical databases
51. Can we learn to distinguish between 'drug-like' and 'non-drug-like' molecules?
52. A scoring scheme for discriminating between drugs and non-drugs
53. Identification of biological activity profiles using substructural analysis and genetic algorithms
54. The properties of known drugs. 1. Molecular frameworks
55. Properties of known drugs. 2. Side chains
56. A knowledge based approach in designing combinatorial or medicinal libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases
57. Drug-like index: A new approach to measure drug-like compounds and their diversity
58. a values by ab initio methods